The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial
Open accessAbstract
Importance: Catheter ablation is more effective than drug therapy in restoring sinus rhythm in patients with atrial fibrillation (AF), but its incremental effect on long-term quality of life (QOL) is uncertain. Objective: To determine whether catheter ablation is more beneficial than conventional drug therapy for improving QOL in patients with AF. Design, Setting, and Participants: An open-label randomized clinical trial of catheter ablation vs drug therapy in 2204 symptomatic patients with AF older than 65 years or 65 years or younger with at least 1 risk factor for stroke. Patients were enrolled from November 2009 to April 2016 from 126 centers in 10 countries. Follow-up ended in December 2017. Interventions: Pulmonary vein isolation, with additional ablation procedures at the discretion of the investigators, for the catheter ablation group (n = 1108) and standard rhythm and/or rate-control drugs selected and managed by investigators for the drug therapy group (n = 1096). Main Outcomes and Measures: Prespecified co-primary QOL end points at 12 months, including the Atrial Fibrillation Effect on Quality of Life (AFEQT) summary score (range, 0-100; 0 indicates complete disability and 100 indicates no disability; patient-level clinically important difference, ≥5 points) and the Mayo AF-Specific Symptom Inventory (MAFSI) frequency score (range, 0-40; 0 indicates no symptoms and 40 indicates the most severe symptoms; patient-level clinically important difference, ≤-1.6 points) and severity score (range, 0-30; 0 indicates no symptoms and 30 indicates the most severe symptoms; patient-level clinically important difference, ≤-1.3 points). Results: Among 2204 randomized patients (median age, 68 years; 1385 patients [63%] were men, 946 [43%] had paroxysmal AF, and 1256 [57%] had persistent AF), the median follow-up was 48.5 months, and 1968 (89%) completed the trial. The mean AFEQT summary score was more favorable in the catheter ablation group than the drug therapy group at 12 months (86.4 points vs 80.9 points) (adjusted difference, 5.3 points [95% CI, 3.7-6.9]; P < .001). The mean MAFSI frequency score was more favorable for the catheter ablation group than the drug therapy group at 12 months (6.4 points vs 8.1 points) (adjusted difference, -1.7 points [95% CI, -2.3 to -1.2]; P < .001) and the mean MAFSI severity score was more favorable for the catheter ablation group than the drug therapy group at 12 months (5.0 points vs 6.5 points) (adjusted difference, -1.5 points [95% CI, -2.0 to -1.1]; P < .001). Conclusions and Relevance: Among patients with symptomatic atrial fibrillation, catheter ablation, compared with medical therapy, led to clinically important and significant improvements in quality of life at 12 months. These findings can help guide decisions regarding management of atrial fibrillation. Trial Registration: ClinicalTrials.gov Identifier: NCT00911508.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument
Reilly, M. C., Zbrozek, A. S., & Dukes, E. M. (1993) · PharmacoEconomics · doi:10.2165/00019053-199304050-00006 · Cited by 3,071
Hlatky, M. A., Boineau, R. E., Higginbotham, M. B., Lee, K. L., Mark, D. B., Califf, R. M., Cobb, F. R., & Pryor, D. B. (1989) · The American Journal of Cardiology · doi:10.1016/0002-9149(89)90496-7 · Cited by 1,736
Self-citationPacker, D. L., Mark, D. B., Robb, R. A., Monahan, K. H., Bahnson, T. D., Poole, J. E., Noseworthy, P. A., Rosenberg, Y. D., Jeffries, N., Mitchell, L. B., et al. (2019) · JAMA · doi:10.1001/jama.2019.0693 · Cited by 1,503
Self-citationWilber, D. J., Pappone, C., Neuzil, P., De Paola, A., Marchlinski, F., Natale, A., Macle, L., Daoud, E. G., Calkins, H., Hall, B., et al. (2010) · JAMA · doi:10.1001/jama.2009.2029 · Cited by 1,170
Wazni, O. M., Marrouche, N. F., Martin, D. O., Verma, A., Bhargava, M., Saliba, W., Bash, D., Schweikert, R., Brachmann, J., Gunther, J., et al. (2005) · JAMA · doi:10.1001/jama.293.21.2634 · Cited by 1,121
A Focal Source of Atrial Fibrillation Treated by Discrete Radiofrequency Ablation
Jai¨s, P., Hai¨ssaguerre, M., Shah, D. C., Chouairi, S., Gencel, L., Hocini, M., & Cle´menty, J. (1997) · Circulation · doi:10.1161/01.cir.95.3.572 · Cited by 1,117
Circumferential Pulmonary-Vein Ablation for Chronic Atrial Fibrillation
Oral, H., Pappone, C., Chugh, A., Good, E., Bogun, F., Pelosi, F., Bates, E. R., Lehmann, M. H., Vicedomini, G., Augello, G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa050955 · Cited by 976
Stanford Presenteeism Scale: Health Status and Employee Productivity
Koopman, C., Pelletier, K. R., Murray, J. F., Sharda, C. E., Berger, M. L., Turpin, R. S., Hackleman, P., Gibson, P., Holmes, D. M., & Bendel, T. (2002) · Journal of Occupational and Environmental Medicine · doi:10.1097/00043764-200201000-00004 · Cited by 821
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation
Cosedis Nielsen, J., Johannessen, A., Raatikainen, P., Hindricks, G., Walfridsson, H., Kongstad, O., Pehrson, S., Englund, A., Hartikainen, J., Mortensen, L. S., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113566 · Cited by 720
Pappone, C., Augello, G., Sala, S., Gugliotta, F., Vicedomini, G., Gulletta, S., Paglino, G., Mazzone, P., Sora, N., Greiss, I., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.08.037 · Cited by 686
Morillo, C. A., Verma, A., Connolly, S. J., Kuck, K. H., Nair, G. M., Champagne, J., Sterns, L. D., Beresh, H., Healey, J. S., Natale, A., et al. (2014) · JAMA · doi:10.1001/jama.2014.467 · Cited by 667
Interpreting treatment effects in randomised trials
Guyatt, G. H., Juniper, E. F., Walter, S. D., Griffith, L. E., & Goldstein, R. S. (1998) · BMJ · doi:10.1136/bmj.316.7132.690 · Cited by 516
Spertus, J., Dorian, P., Bubien, R., Lewis, S., Godejohn, D., Reynolds, M. R., Lakkireddy, D. R., Wimmer, A. P., Bhandari, A., & Burk, C. (2011) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.110.958033 · Cited by 485
Successful Catheter Ablation of Atrial Fibrillation
HAÏSSAGUERRE, M., GENCEL, L., FISCHER, B., LE MÉTAYER, P., POQUET, F., MARCUS, F. I., & CLEMÉNTY, J. (1994) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.1994.tb01146.x · Cited by 334
Bubien, R. S., Knotts-Dolson, S. M., Plumb, V. J., & Kay, G. N. (1996) · Circulation · doi:10.1161/01.cir.94.7.1585 · Cited by 284
Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation
Dorian, P., Paquette, M., Newman, D., Green, M., Connolly, S. J., Talajic, M., & Roy, D. (2002) · American Heart Journal · doi:10.1067/mhj.2002.122518 · Cited by 247
Long-Term Quality of Life After Ablation of Atrial Fibrillation
Wokhlu, A., Monahan, K. H., Hodge, D. O., Asirvatham, S. J., Friedman, P. A., Munger, T. M., Bradley, D. J., Bluhm, C. M., Haroldson, J. M., & Packer, D. L. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.040 · Cited by 242
Self-citationPacker, D. L., Mark, D. B., Robb, R. A., Monahan, K. H., Bahnson, T. D., Moretz, K., Poole, J. E., Mascette, A. M., Rosenberg, Y., Jeffries, N. O., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.02.015 · Cited by 151
Self-citationInterpreting Change in Scores on Patient-Reported Outcome Instruments
Coon, C. D., & Cappelleri, J. C. (2015) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479015622667 · Cited by 109
Understanding the Role of P Values and Hypothesis Tests in Clinical Research
Mark, D. B., Lee, K. L., & Harrell, F. E. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.3312 · Cited by 89
Self-citationAssessing quality-of-life outcomes in cardiovascular clinical research
Mark, D. B. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.10 · Cited by 64
Self-citation
Cited by
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 9,971
Self-citationVan Gelder, I. C., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Crijns, H. J. G. M., De Potter, T. J. R., Dwight, J., Guasti, L., Hanke, T., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae176 · Cited by 3,024
2023 ESC guidelines for the management of cardiomyopathies
Arbelo, E., Protonotarios, A., Gimeno, J. R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C. R., Biagini, E., Blom, N. A., de Boer, R. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad194 · Cited by 2,844
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001193 · Cited by 2,765
Self-citation
Metadata
- Authors
- Mark, D. B., Anstrom, K. J., Sheng, S., Piccini, J. P., Baloch, K. N., Monahan, K. H., Daniels, M. R., Bahnson, T. D., Poole, J. E., Rosenberg, Y., Lee, K. L., Packer, D. L., & for the CABANA Investigators
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2019-04-02
- Volume
- 321
- Issue
- 13
- Pages
- 1275
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2920839885
- Cited by
- 624
- References
- 22
- FWCI
- 50.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.